COPD: sex differences in comorbidities, outcomes in ARCTIC cohort

  • Lisspers K & al.
  • NPJ Prim Care Respir Med
  • 10.12.2019

  • von Miriam Davis, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • ARCTIC, a real-world cohort study of almost 17,500 patients with COPD in 52 primary care practices, showed sex differences in outcomes, with higher rates of exacerbations and hospitalizations among women and greater overall mortality in men.

Why this matters

  • Findings suggest the need to reduce sex differences through better diagnosis and treatment.

Study design

  • A retrospective cohort study of patients with COPD (N=17,479) in 52 primary care practices in Sweden.
  • Funding: Novartis Pharma AG.

Key results

  • Mean follow-up, 12.4 years.
  • Women at a disadvantage:
    • Greater comorbid asthma, fractures, rheumatoid arthritis, depression, anxiety (all P<.0001>
    • Greater comorbid osteoporosis and rhinitis (no P value given).
    • Greater number of moderate exacerbations (6.66 vs 4.66; P<.0001 and exacerbations of any severity vs p>
    • Higher rate of earlier exacerbation (HR, 1.12; P<.0001>
    • Greater number of COPD-related hospitalizations per year (P=.007).
    • Greater number of COPD drug prescriptions (no overall P given).
  • Men at a disadvantage:
    • Greater comorbidity with type 1 and 2 diabetes, kidney disease, and cardiovascular disease (all P<.0001>
    • Greater overall mortality (45% vs 38% in women; P<.0001>
    • Smaller median survival time from COPD diagnosis to death (9.0 vs 11.1 years; no P value given).
  • No sex differences in severe exacerbations (P=.60).

Limitations

  • No P values are given for some comorbidities and outcomes.
  • Retrospective, observational design.